Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases

Abstract

Nucleoside analogs, nucleic acids and pharmaceutical agents comprising same, and to the use of said nucleoside analogs, nucleic acids and pharmaceutical agents in the diagnosis, prophylaxis or therapy of a viral, bacterial, fungicidal and/or parasitic infection, or of cancer, particularly of hepatitis infections. The invention also relates to a method for the preparation of said nucleoside analogs and to a kit and the use thereof in the prophylaxis and therapy of viral diseases, particularly of hepatitis infections. As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.

Dependencies are inferred from the claim text.